Dupilumab for asthma remission study
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether dupilumab can help people with moderate-to-severe asthma achieve clinical remission. It may be an option if you have asthma with high levels of certain inflammatory markers and have had at least one asthma attack in the last 2 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had asthma for at least 6 months, with evidence of variable airflow (like a positive reversibility test or peak flow variability).
- You have high levels of type-2 inflammation markers: blood eosinophils ≥0.3×10^9/L and FeNO ≥35 ppb at screening.
- You have had at least 1 asthma attack in the last 2 years that required oral steroids or an emergency/hospital visit.
- You are taking a medium or high dose of inhaled corticosteroids (e.g., fluticasone ≥250 mcg/day) for at least 3 months, with or without other controllers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This trial tests whether patients with well-controlled severe asthma can safely stop taking dupilumab after at least 3 years of treatment. If you qualify, you may be able to stop the medication and see if your asthma stays under control.
This study looks at how well and how safely the medicine Dupilumab works for children whose asthma is not well-controlled with their current inhalers. The goal is to see if it can help reduce asthma attacks and improve daily life.
Hear when a new Asthma Control trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.